Back To Search Instructions
13 protocols meet the specified criteria
Disease Site: Non-Hodgkin's Lymphoma
Protocol No.TitleStatus
0500000226Arizona Lymphoid Tissue and Blood Repository (ALTBR)Open
0500000303Phase II Trial of Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin's LymphomaOpen
0800001071A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas (ProtocolOpen
0900000679A Phase II Study Of Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) For Treatment Of Hematologic Malignancies And Hematopoietic Failure StatesOpen
0900000967Lymphoma Outcomes and Epidemiological DatabaseOpen
1000000602Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (COMPLETE)Open
1100000353A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma (M12-175) Open
1100000429Phase 1b, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaOpen
1100000642S1001, "A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)"Open
1200000288A Phase II Exploratory Study of PXD101 Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma (Stage 1)Open
1300000486M13-835: An Extension Study of ABT-199 in Subjects with Advanced Non-Hodgkin's LymphomaOpen
1300000498M13-364: A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199Open
NMDP2011-0624A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen